Your browser doesn't support javascript.
loading
Classification of performance validity and symptom validity using the Trauma Symptom Inventory-2.
Pachet, Arlin K; Malcolm, Darnel N; Liu, Irene; Brown, Cassandra; Vanderveen, Sarah; Tan, Aiko.
Afiliação
  • Pachet AK; Pachet Assessment and Rehabilitation, Calgary, Canada.
  • Malcolm DN; University of Calgary, Calgary, Canada.
  • Liu I; Pachet Assessment and Rehabilitation, Calgary, Canada.
  • Brown C; Pachet Assessment and Rehabilitation, Calgary, Canada.
  • Vanderveen S; Alberta Health Services, Calgary, Canada.
  • Tan A; Alberta Health Services, Calgary, Canada.
Appl Neuropsychol Adult ; : 1-8, 2022 Nov 15.
Article em En | MEDLINE | ID: mdl-36377630
The Trauma Symptom Inventory-Second Edition (TSI-2) is garnering research interest as a symptom validity test in the evaluation of trauma-related disorders. However, there has been limited empirical validation of its validity scales in clinical and forensic real-world settings. This study evaluated the ability of the TSI-2 Atypical Response (ATR) scale to discriminate response bias in cognitive performance and symptom reporting in a large sample of disability and compensation-seeking claimants. This retrospective chart review included 296 adults with a known history of trauma exposure or claimed trauma-related psychological injury who underwent neuropsychological and/or comprehensive psychological assessment in a private neuropsychology clinic. The discriminability of the ATR scale to classify credible versus non-credible cognitive profiles and symptom reporting were analyzed by AUC-ROCs. Overall, the ATR scale demonstrated poor discriminability of assessment validity based on the Word Memory Test, Victoria Symptom Validity Test, and Minnesota Multiphasic Personality Inventory-2-Restructured Form. The ATR scale had fair discriminatory ability of only one of the over-reporting scales (F-r), with an ROC area of .73, p = .001. However, the test publisher's proposed ATR cut-offs of ≥8 for screening, research, and normal groups, and ≥15 in forensic and clinical settings revealed significant issues with sensitivity and specificity. These results suggest that the TSI-2 should be paired with other established performance validity and symptom validity tests in clinical assessments and not be used as the primary or sole indicator of assessment validity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Appl Neuropsychol Adult Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Appl Neuropsychol Adult Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá País de publicação: Estados Unidos